welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Mayo Clinic Researcher Finds Potential Target to Control Rare Genetic Disease That Strikes in Teen Years
A new study from researchers at Mayo Clinic Center for Individualized Medicine, described in the New England Journal of Medicine, reveals patients with the most severe FAP disease may benefit from a novel combination therapy. The study points to a possible target for intervention and prevention.
Author Niloy Jewel (Jewel) Samadder, M.D., a gastroenterologist and cancer genetics expert at Mayo Clinic’s campus in Ariz., and his colleagues, studied 171 patients with FAP who had various disease stages, at 20 centers in the U.S., Canada and Europe. Researchers evaluated the benefit and safety of the combination of eflornithine and sulindac compared to each drug alone. The investigation represents the largest international phase III FAP trial to date involving pharmaco-prevention — the use of a medication to prevent the need for surgery or other disease progression.

expertly curated content related to this topic
- Dietary Polyamine Intake and Risk of Colorectal Adenomatous PolypsBACKGROUND : Putrescine, spermidine, and...
- Bonnies Diary March 08https://jtvcancersupport.com/embed/46053...
- Endoscopic Management of Familial Adenomatous Polyposis in Patients Refusing ColectomyBACKGROUND AND STUDY AIMS: Colectomy pr...
- A Randomized Controlled Trial of Eicosapentaenoic acid and/or Aspirin For Colorectal Adenoma Prevention During Colon...BACKGROUND: The naturally-occurring ome...
- Thetis Pharmaceuticals Awarded Key Patent on HEALER TechnologyThetis Pharmaceuticals LLC, a privately-...
- Turmeric Supplementation on Polyp Number and Size in Patients With Familial Adenomatous PolyposisA Phase 2, randomized, double blind, pla...
- Gliotoxin Inhibits Proliferation and Induces Apoptosis in Colorectal Cancer CellsThe discovery of new bioactive compounds...